The biopharmaceutical landscape is evolving rapidly, with increasingly complex antibody modalities such as multispecifics and antibody–drug conjugates (ADCs) pushing the boundaries of therapeutic design. While these innovative formats offer new treatment possibilities, they also introduce greater developability challenges, including increased aggregation risks and higher viscosity, poor solubility, and reduced stability. So, how are in silico developability practices adapting to support both traditional monoclonal antibodies (mAbs) and next-generation antibody formats?
At this scientific gathering, you will discover innovative in silico approaches and practical workflows that support predictive assessment of key physicochemical properties across mAbs and advanced modalities early in the discovery process; ultimately guiding a rational construct design and reducing downstream risks related to formulation and manufacturability.
What to expect?
- Scientific talks from pharma researchers sharing their latest discoveries and in silico workflows for mitigating developability risks
- An expert panel providing insights and best practices for early developability assessment, featuring both early and late-stage experts
- Networking opportunities with industry peers and casual discussions over food and drinks
Secure your place today and join us in Basel or online for an insightful and interactive session!
For furth Infomation please contact:
Marija Martini |
